ORC2 and central nervous system cancer: The use of the same shORC6-s1 treatment along with puromycin selection led to a substantial reduction in ORC6 mRNA across these glioma cells (Fig. 4I), while the expression of ORC2 mRNA remained unaltered (Fig. 4J).